Teligent (NASDAQ:TLGT) Downgraded to Sell at Zacks Investment Research

Zacks Investment Research downgraded shares of Teligent (NASDAQ:TLGT) from a hold rating to a sell rating in a research report report published on Thursday, Zacks.com reports.

According to Zacks, “Teligent, Inc. is a specialty generic pharmaceutical company, develops, manufactures and markets topical formulations primarily in the United States. It sells generic pharmaceutical products in topical, injectable, complex and ophthalmic dosage forms. Teligent Inc., formerly known as IGI Laboratories, Inc., is based in Buena, New Jersey. “

Separately, ValuEngine lowered shares of Teligent from a buy rating to a hold rating in a research report on Thursday, May 23rd.

Shares of NASDAQ:TLGT opened at $0.70 on Thursday. The stock has a market capitalization of $36.89 million, a price-to-earnings ratio of -2.12 and a beta of 1.59. Teligent has a 1-year low of $0.42 and a 1-year high of $4.52. The company’s fifty day moving average is $0.68 and its two-hundred day moving average is $0.97. The company has a debt-to-equity ratio of 23.23, a quick ratio of 0.86 and a current ratio of 1.61.

Teligent (NASDAQ:TLGT) last issued its earnings results on Monday, August 5th. The company reported ($0.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.01). The business had revenue of $18.34 million for the quarter, compared to analyst estimates of $17.58 million. Teligent had a negative return on equity of 102.17% and a negative net margin of 46.67%. Sell-side analysts expect that Teligent will post -0.18 EPS for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. Sanders Morris Harris LLC grew its position in Teligent by 81.7% in the 2nd quarter. Sanders Morris Harris LLC now owns 3,814,012 shares of the company’s stock valued at $2,404,000 after buying an additional 1,715,239 shares in the last quarter. First Light Asset Management LLC grew its position in Teligent by 113.3% in the 2nd quarter. First Light Asset Management LLC now owns 3,227,003 shares of the company’s stock valued at $2,033,000 after buying an additional 1,713,824 shares in the last quarter. AMI Asset Management Corp grew its position in Teligent by 0.5% in the 1st quarter. AMI Asset Management Corp now owns 2,727,695 shares of the company’s stock valued at $3,164,000 after buying an additional 13,403 shares in the last quarter. Geode Capital Management LLC grew its position in Teligent by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 479,485 shares of the company’s stock valued at $656,000 after buying an additional 17,951 shares in the last quarter. Finally, NJ State Employees Deferred Compensation Plan grew its position in Teligent by 9.1% in the 2nd quarter. NJ State Employees Deferred Compensation Plan now owns 240,000 shares of the company’s stock valued at $151,000 after buying an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 61.02% of the company’s stock.

Teligent Company Profile

Teligent, Inc, a specialty generic pharmaceutical company, develops, manufactures, markets, and sells generic topical, branded generic, and generic injectable pharmaceutical products in the United States and Canada. It offers generic pharmaceutical products in topical, injectable, complex, and ophthalmic dosage forms.

Read More: What is the Producer Price Index (PPI)?

Get a free copy of the Zacks research report on Teligent (TLGT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.